Holen Sie sich die Stockscreener-App
0.7198
2.98%
0.0208
Schlusskurs vom Vortag:
$0.699
Offen:
$0.69
24-Stunden-Volumen:
116.00K
Relative Volume:
0.52
Marktkapitalisierung:
$64.57M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.15M
KGV:
-0.791
EPS:
-0.91
Netto-Cashflow:
$-31.63M
1W Leistung:
+1.38%
1M Leistung:
+11.94%
6M Leistung:
-17.57%
1J Leistung:
-70.01%
1-Tages-Spanne:
$0.6798
$0.7198
1-Wochen-Bereich:
$0.6752
$0.728
52-Wochen-Spanne:
$0.49
$2.75
Context Therapeutics Inc Stock (CNTX) Company Profile
Firmenname
Context Therapeutics Inc
Sektor
Branche
Telefon
267-225-7416
Adresse
2001 MARKET STREET, PHILADELPHIA
Vergleichen Sie CNTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.7198 | 62.70M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-21 | Eingeleitet | William Blair | Outperform |
| 2025-01-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-11-25 | Eingeleitet | D. Boral Capital | Buy |
| 2024-05-16 | Eingeleitet | Piper Sandler | Overweight |
Context Therapeutics Inc Aktie (CNTX) Neueste Nachrichten
Published on: 2025-08-10 04:36:20 - Newser
Chart based exit strategy for Context Therapeutics Inc.Real Trader Watchlist with Entry Targets - Newser
Best data tools to analyze Context Therapeutics Inc. stockFuture Growth Stock Forecasting Strategy - Newser
Tools to monitor Context Therapeutics Inc. recovery probabilityFree Real Time Stock Movement Analysis - Newser
Context Therapeutics Inc. Stock Support and Resistance Levels You Should KnowRisk Adjusted Trade Signal Screening Tool - Newser
Context Therapeutics Highlights Pipeline Progress, Reports $8.8M Loss in Q2 - MSN
How sentiment analysis helps forecast Context Therapeutics Inc.AI Powered Buy Point Forecast Planner - Newser
Analyzing net buyer seller activity in Context Therapeutics Inc.Free Entry and Exit Strategy Optimizer Tool - Newser
What makes Context Therapeutics Inc. stock price move sharplyWeekly Chart-Based Forecast for Traders - Newser
Context Therapeutics Inc. shares fall 2.58% intraday as Genmab's epcoritamab development program progresses. - AInvest
Quantitative breakdown of Context Therapeutics Inc. recent moveWeekly Hot Stocks Based on Volume Flow - Newser
How to read the order book for Context Therapeutics Inc.Free Trend Following Strategy With Stop Loss - Newser
Detecting support and resistance levels for Context Therapeutics Inc.Capital Growth Summary Over Five Years - Newser
D. Boral Capital Raises PT to $9 on Context Therapeutics - AInvest
Context Therapeutics: HC Wainwright Downgrades to Buy with $4 PT. - AInvest
Context Therapeutics Q2 net loss widens, cash funds ops into 2027 - MarketScreener
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results - GlobeNewswire
Context Therapeutics Q2 Earnings: Strong $83.5M Cash Position Funds Two Key Cancer Drug Trials - Stock Titan
How Context Therapeutics Inc. stock performs during market volatilityFree AI-Powered Trade Planning with Indicators - Newser
What technical models suggest about Context Therapeutics Inc.’s comebackShort-Term AI-Based Stock Price Forecast - Newser
Custom strategy builders for tracking Context Therapeutics Inc.Safe and Scalable Return Strategy Blueprint - Newser
Is Context Therapeutics Inc. a good long term investmentUnlock market-leading stock analysis - Jammu Links News
Why Context Therapeutics Inc. stock attracts strong analyst attentionWeekly Stock Market Strategy Summary - Newser
When is Context Therapeutics Inc. stock expected to show significant growthNavigate market shifts with confidence - Jammu Links News
How does Context Therapeutics Inc. compare to its industry peersUnlock powerful trading signals and alerts - Jammu Links News
Is it the right time to buy Context Therapeutics Inc. stockCapitalize on momentum-driven investment opportunities - Jammu Links News
What are the latest earnings results for Context Therapeutics Inc.Outstanding investment returns - Jammu Links News
What is the risk reward ratio of investing in Context Therapeutics Inc. stockRapid wealth multiplication - Jammu Links News
How strong is Context Therapeutics Inc. company’s balance sheetIdentify breakout stocks before they peak - Jammu Links News
What is the dividend policy of Context Therapeutics Inc. stockRapid wealth accumulation - Jammu Links News
What institutional investors are buying Context Therapeutics Inc. stockMaximize gains with expert analysis - Jammu Links News
How many analysts rate Context Therapeutics Inc. as a “Buy”High-performance stocks for savvy investors - Jammu Links News
Wyckoff Accumulation Phase Possible in Context Therapeutics Inc.Daily Momentum Screener With Alerts Launched - metal.it
What analysts say about Context Therapeutics Inc. stock outlookImmediate Entry Point Prediction Strategy - Newser
Full technical analysis of Context Therapeutics Inc. stockFree Community Strategy With High Win Rate - Newser
Finanzdaten der Context Therapeutics Inc-Aktie (CNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Context Therapeutics Inc-Aktie (CNTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Levit Alex C. | Chief Legal Officer, Corp. Sec |
Jun 06 '25 |
Buy |
0.58 |
20,000 |
11,520 |
29,000 |
| Minai-Azary Jennifer Lynn | Chief Financial Officer |
Jun 06 '25 |
Buy |
0.64 |
40,010 |
25,486 |
80,010 |
0.24%
3.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):